Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Human Pathology|July 29, 2026
Molecular Subtypes and Genetic Diagnostics in B-cell Acute Lymphoblastic LeukemiaRoberta S Azevedo, L Jeffrey Medeiros, Sanam Loghavi, et al.
Blood|December 3, 2025
Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemiaRoberta S Azevedo, Elias Jabbour, Hagop M Kantarjian, et al.
Haematologica|November 21, 2024
Investigating the influence of germline ATM variants in chronic lymphocytic leukemia on cancer vulnerabilityRoberta S Azevedo, Francesca Morelli, Kiyomi Mashima, et al.
Leukemia & Lymphoma|August 9, 2025
Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phaseOmer Karrar, Hagop Kantarjian, Fadi G Haddad, et al.
Haematologica|June 26, 2025
Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell / myeloid mixed phenotype acute leukemiaRoberta S Azevedo, Wei-Ying Jen, Danielle Hammond, et al.
Expert Opinion on Biological Therapy|December 25, 2025
The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasmRoberta S Azevedo, Zohra Nooruddin, Sumeet Bhatia, et al.
Leukemia|July 16, 2026
Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvageRoberta S Azevedo, Elias Jabbour, Nitin Jain, et al.
American Journal of Clinical Pathology|August 15, 2025
Mutational signature analysis of chronic lymphocytic leukemia uncovering genomic patterns and prognostic implicationsAli AlJabban, Roberta S Azevedo, Katherine Antel, et al.
Blood Advances|May 27, 2026
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AMLNicholas J Short, Hagop M Kantarjian, Naval G Daver, et al.
Pageof 1